Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines

European Journal of Cancer

Volumn 36, Issue 16, 2000, Pages 2120-2127

  Jonsson, E ^a   Dhar, S ^a   Jonsson, B ^a   Nygren, P ^a   Graf, W ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Camptothecin derivative; Cytotoxic drug; Cytotoxicity assay; Drug development; Human tumour cell; Topoisomerase I inhibitor; Tumour cell line

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DOXORUBICIN; DRUG METABOLITE; IDARUBICIN; IRINOTECAN; PRODRUG; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; FLUOROMETRY; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; METHODOLOGY; OVARY CANCER; PRIORITY JOURNAL; SAMPLE; TUMOR CELL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUOROMETRY; HUMAN; NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0033815674     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00289-6     Document Type: Article

References (34)

1. Current perspectives on camptothecins in cancer treatment
2. Future directions for clinical research with cpt-11 (irinotecan)
3. Topoisomerase I inhibitors; review and update
4. Irinotecan versus infusional 5-fluorouracil; a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil
5. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
6. Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)
7. Topotecan in colorectal cancer263a phase II study of the EORTC early clinical trials group
8. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patiens with colorectal cancer
9. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts; lack of cross-resistance in vivo in tumours with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin
10. Intracellular roles of SN-38, a metabolite of the camptothecin derivative cpt-11, in the antitumor effect of cpt-11
11. Human tumor carboxyesterase activity correlates with cpt-11 cytotoxicity in vitro
12. Role of carboxylesterase on metabolism of camptothecin analog (cpt-11) in non-small cell lung cancer cell line PC-7 cells
13. Cpt-11 in human colon-cancer cell lines and xenografts; characterization of cellular sensitivity determinants
14. Antitumor activity of a camptothecin derivative, cpt-11, against human tumor xenografts in nude mice
15. Metabolism and pharmacokinetics of the camptothecin analogue cpt-11 in the mouse
16. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice
17. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
18. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamtothecin (cpt-11) administered as a ninety-minute infusion every 3 weeks
19. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
20. Anticancer drug characterization using a human cell line panel representing defined types of drug resistance
21. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26
22. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
23. Characterization of a new drug-resistant human myeloma cell line that expresses p-glycoprotein
24. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels
25. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170 kDa p-glycoprotein
26. Verapamil and cyclosporin A sensitize human kidney tumor cells to vincristine in absence of membrane p-glycoprotein and without apparent changes in the cytoplasmic free Ca2+ concentration
27. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA)
28. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia
29. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen
30. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
31. Cellular resistance to camptothecins
32. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
33. Pharmacokinetics, metabolism and excretion of irinotecan (cpt-11) following iv infusion of 14C-cpt-11 in cancer patients
34. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic